The results of our study are compatible with those of previous studies [19,23,24,32,33,34,35], and LDH was identified as a factor associated with unfavorable outcomes in extensive-stage SCLC patients who received first-line anti-PD-L1 ICIs combined with chemotherapy. This evidence concerns the gene CD274 and small cell lung carcinoma.